Sanofi Consumer Healthcare India Limited reports 28% revenue growth in Q2
Profit up 21% at ₹607 million
Chennai: Sanofi Consumer Healthcare India Limited (BSE:544250 I NSE: SANOFICONR) announced strong financial results for the second quarter of 2025. The company reported a 28% year-on-year increase in Q2 revenue to ₹2,209 million, supported by export operations and successful product launches. Thereby, sales growth stood at 27.5% from Q1 2025 and 27.6% YoY from 2024. Profit after tax (PAT) for the quarter reached ₹607 million, a 21% increase over Q1 2025.
Commenting on the results, Himanshu Bakshi, Managing Director, Sanofi Consumer Healthcare India Limited, said: “Our commitment to delivering high-quality, science-backed products continues to anchor our growth strategy—driven by a focused portfolio, research-led innovation, and an agile organization. This quarter reflects the outcomes of that focused approach, with successful relaunch of two previously recalled products and introduction of a new product. We also commenced export operations allowing us to extend our efforts towards international markets. As we look ahead, we remain steadfast in our purpose to make self-care simpler, more accessible and effective for consumers.”
During the half year, the company launched Allegra D*, a unique proposition in the Allergy segment, also relaunched Depura 60k and Combiflam Suspension* which were recalled voluntarily last year. Other legacy brands such as Avil*, and Depura continue to uphold strong consumer trust and drive long-term relevance in their respective categories.
Financial highlights
• Sale of Products
o Q2 2025: ₹2,209 million
o H1 2025: ₹3,935 million
• Profit After Tax
o Q2 2025: ₹606 million
o H1 2025: ₹1,107 million
Note: Quarter and half-year financials are not directly comparable due to the demerger and voluntary recall of certain variants of key brands.
*P.S.: These medications must be prescribed by a practicing medical professional.
——————————————————————————–
About Combiflam: Launched in 1985 in India, for three decades now Combiflam has cured millions of back, knee, joint, neck, shoulder, fever and body pains. Prescribed variants of Combiflam are tablets, suspensions and cream.
About Allegra: Launched in 1997 in India, this 27 years old brand has seen successful product extensions over the years. From Allegra 120, Allegra 180, Allegra M, Allegra Nasal Spray, Allegra Nasal Duo to now Allegra D. Allegra is used to treat the symptoms of various kinds of allergies in adults and children, some of which are sneezing, itching and hives.
About Sanofi Consumer Healthcare India Limited.
Sanofi Consumer Healthcare India Limited (SCHIL) has emerged as a distinct legal entity following its demerger from Sanofi India Limited. This demerger, executed under the Scheme of Arrangement, was sanctioned by the Mumbai bench of the National Company Law Tribunal and became effective on 1st June 2024. In alignment with Sanofi’s global strategy, SCHIL is now operating independently, with a dedicated focus on the Consumer Healthcare sector.
With an agile business model and strong brands, SCHIL is one of the leading players in India’s consumer healthcare market. Leveraging its global experience in consumer healthcare, Sanofi Consumer Healthcare India Limited (SCHIL) aims to enhance customer wellbeing through its portfolio of products which encompasses Allergy, Digestive Wellness, Pain Care, and Multivitamins and Herbal/Traditional Dietary Supplements. SCHIL’s key brands include Allegra®, DePURA®, Avil®, and Combiflam®. They are dedicated to building a healthier future for their customers by empowering people to take control of their health, through self-care and by addressing their everyday health concerns.
